Lucia Bio

Executive Summary

Lucia Bio is an Australian preclinical biotechnology company focused on developing highly selective oral small-molecule inhibitors of spleen tyrosine kinase (Syk) for peripheral immunology, neurology, and oncology indications. Founded in 2020 and based in Brisbane, the company leverages the University of Queensland’s QEDDI platform to design best-in-class Syk inhibitors with optimized drug-like properties. Syk is a validated target for autoimmune diseases, neuroinflammatory conditions, and hematological cancers; however, existing inhibitors often suffer from poor selectivity or pharmacokinetics. Lucia aims to address these limitations by engineering molecules with enhanced potency, selectivity, and brain penetration for central nervous system indications. The company has raised $3 million to date and is currently in the preclinical stage, advancing its lead candidate toward IND-enabling studies. Lucia Bio's strategy centers on addressing high unmet need in both peripheral and central indications, including rheumatoid arthritis, multiple sclerosis, and B-cell malignancies. By targeting Syk, which plays a key role in immune receptor signaling and inflammatory pathways, the company hopes to offer safer and more efficacious alternatives to existing therapies. With a strong academic foundation and a focused pipeline, Lucia Bio is positioned to attract additional funding and partnership opportunities as it progresses toward clinical development. Key upcoming milestones include completion of IND-enabling toxicology studies, GMP manufacturing, and the initiation of first-in-human trials, which could serve as significant value inflection points for the company.

Upcoming Catalysts (preview)

• Q4 2026Completion of IND-enabling toxicology studies70% success
• H2 2027First-in-human trial initiation40% success
• TBDPartnership or licensing deal for lead program30% success